Radiofrequency microneedling tips hold their needles in a fixed matrix. The tip is pressed into the skin, the needles penetrate to a set depth, and current flows between them. Each needle leaves a puncture at the surface and a small zone of coagulated tissue beneath it.
That is the whole explanation. The marks are not a complication in themselves. They are the visible footprint of a fractional treatment, which is a treatment that deliberately leaves untreated skin between the treated columns so healing is quicker.
What varies between machines is how dense that footprint is, how deep it goes, and whether the skin surface is injured at each entry point. Those are documented device specifications, and they are the reason the same treatment name produces a different-looking pattern in different clinics.
These figures come from the devices' own FDA paperwork or, where noted, from manufacturer labelling.
A denser array in a similar footprint puts the dots closer together. A sparse array, or a handful of electrode pairs, leaves a coarser and more separated pattern. Neither is better; they are different tools.
Insulated needles are coated along the shaft with only the tip exposed, so radiofrequency is released at depth. A 2016 study demonstrated this directly on tissue samples: with insulated needles the coagulation zone was a clearly demarcated, roughly oval area confined to the dermis and not involving the epidermis - the outer layer of skin.
Non-insulated needles conduct current along the entire shaft, including where the needle crosses the surface, so each entry point takes a thermal injury at skin level. That surface injury is the physical substrate for a visible dot at every needle position.
Two cautions matter here. First, there is no published head-to-head trial comparing insulated and non-insulated needles, in any skin type - the reasoning is mechanistic, not measured, and non-insulated devices have produced good outcomes in practice, with a 44-person study in Fitzpatrick III to V reporting pigment change in 2 of 40 people. Second, most manufacturers' insulation claims are not in their FDA paperwork. Genius's filing states it explicitly. For Potenza, Secret RF, Vivace, Sylfirm X, Scarlet, Agnes, PiXel8-RF and Profound, insulation status is not stated in the retrievable summaries, so what you are told about it is a manufacturer claim. It is still worth asking - just worth knowing what kind of answer it is.
A 2025 study combining pig-skin histology with 30 patients found a near-linear relationship between energy per needle, across 20 to 100 mJ, and the volume of coagulated tissue - a correlation of 0.976. More energy per pin means a bigger heat zone at each pin, which means a more visible mark. This is a settings decision, not an inevitability. Two of that paper's four authors were affiliated with a device manufacturer.
Regulators have made the same link. The FDA clearance for the Morpheus8 applicator carries an explicit limitation: above 62 mJ per pin, use is limited to Fitzpatrick skin types I to IV. Energy per pin is the variable FDA tied to skin type safety.
Pass overlap is the third mechanism people raise - stacking the array so grids intersect concentrates energy where they overlap. That is mechanically plausible and has never been quantified in any published study.
Quite a lot is not known, and it is better said plainly.
What can be said is what general recovery data supports. Water loss through the skin - a direct measure of how compromised the barrier is - peaks on days one to three and is back to baseline by day seven in a 20-person study. Downtime was reported as three to four days in the study of the lower face and neck with insulated needles. Published recovery data describes roughly a week. Marks still clearly visible well beyond that are outside what any study describes, and should be reviewed rather than waited out.
Three questions are worth asking before a first treatment, and all three now have a reason behind them.
Daily broad-spectrum sunscreen through the treatment course and afterwards is the single best-supported aftercare instruction, on the strength of documented pigment risk in the weeks after treatment.
If you get cold sores, say so when you book - not on the day. Antiviral medicine is started in advance, so it has to be prescribed before the appointment. There is no published data on cold sore reactivation after radiofrequency microneedling specifically; the precaution is carried over from laser resurfacing, where reactivation is well documented and prophylaxis is standard.
Also mention a pacemaker or an implantable defibrillator, and any metal implant near the treatment area. These are labelled contraindications for radiofrequency devices and are precautionary rather than tested - the right people to advise you are your cardiology team. Mention a history of keloid or thickened scarring too.